Cronos Group Soars on Surge in Trading Volume

Cronos Group Inc. (NASDAQ:CRON) experienced exceptional trading volume on Tuesday, with 4,756,022 shares changing hands, marking a 91% surge from the previous session's volume. The stock closed at $2.67, up from its previous closing price of $2.49.

Cronos Group Shares Soar Amid Surge in Trading Volume

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the cannabinoid industry, witnessed a notable surge in trading activity on Tuesday. The company's stock volume reached approximately 4,756,022 shares, representing a significant 91% increase from the previous session's volume of 2,487,493 shares. The stock closed the day at $2.67, up from its previous close of $2.49.

Analyst Coverage

Bank of America recently upgraded its price target on Cronos Group shares, raising it from $1.78 to $2.00. However, the firm maintained an "underperform" rating for the company in a research note dated December 28th, 2023.

Stock Performance and Valuation

Cronos Group shares have gained 6.0% year-to-date. The company currently has a market capitalization of $1.01 billion, a P/E ratio of -13.89, and a beta of 1.13. Its 50-day moving average price stands at $2.14, while its 200-day moving average price is $2.05.

Financial Results

Cronos Group last reported its quarterly financial results on February 29th, 2023. The company posted a loss of $0.05 per share for the quarter. Revenue for the period amounted to $23.92 million, falling short of the consensus estimate of $25.15 million. Cronos Group's return on equity and net margin were negative, at -3.99% and -84.15%, respectively.

Earnings Outlook

Analysts anticipate that Cronos Group Inc. will report a loss of $0.01 per share for the current fiscal year.

Institutional Ownership

Hedge funds and other institutional investors have recently adjusted their positions in Cronos Group. Chesapeake Capital Corp IL established a $25,000 stake in the company during the fourth quarter, while Cetera Investment Advisers acquired a $38,000 stake in the same period. Deutsche Bank AG significantly increased its holdings by 21,218.6%, purchasing 14,853 additional shares during the fourth quarter. Quantbot Technologies LP and Cetera Advisor Networks LLC initiated new positions in Cronos Group in the second and second quarters, respectively. Institutional investors collectively own 8.63% of the company's outstanding shares.

Company Profile

Cronos Group Inc. is engaged in the production and distribution of cannabinoid products. The company operates in the United States, cultivating, manufacturing, and marketing cannabis and cannabis-derived products for medical and adult-use markets. Additionally, it manufactures, markets, and distributes hemp-derived supplements and cosmetic products under the Lord Jones brand through various distribution channels.

Recommendations

MarketBeat, a platform that tracks top-rated research analysts and their stock recommendations, has identified five companies that analysts are bullish on. Notably, Cronos Group is not included in this list of recommended stocks.

Disclaimer

This article is for informational purposes only and should not be considered investment advice. Investors should conduct due diligence and consult with a financial professional before making any investment decisions.